# Haploidentical Stem Cell Transplantation for Patients without a Matched Sibling or Unrelated Donor

A Phase II Clinical Trial: Two-arm Clinical Trial for Patients with Hematologic Malignancies and Mismatched Donors – Haploidentical and 1 Antigen Mismatched Related or Unrelated - Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide

## Objective:

- To determine the safety and 100-day non-relapse mortality of T-cell replete allogeneic stem cell transplantation using 3 drugs as conditioning followed by high-dose post –transplant cyclophosphamide

## Eligibility Criteria:

- Patients with high risk hematologic malignancies requiring a stem cell transplant without a matched donor
- Up to 60 years old
- ECOG performance status 0-1
- Adequate organ function

## Benefits for Patients:

- May produce prolonged disease-free survival in patients with hematologic malignancies
- Provides an opportunity for allogeneic hematopoietic stem-cell transplantation for patients who lack a matched related or unrelated donor

## Procedures:

- Two-arm clinical trial for patient with hematologic malignancies and mismatched donors
- Arm 1: Haploidentical and Arm 2: One antigen mismatch related or unrelated
- Treatment plan is the same for both arms; uses a T-cell replete allograft and high-dose post-transplant cyclophos phamide followed by tacrolimus and mycophenolate
- Conditioning regimen includes Fludarabine 160 mg/m2, Melphalan 140mg/m2 and Thiotepa 10mg/kg; Infusion of bone marrow stem cells on day 0
- Two doses of cyclophosphamide are administered on day +3 and +4 post transplant for GVHD prevention
- Patients will be admitted for approximately one month and are required to be in Houston for approximately 3 months after transplant

## Protocol # 2009-0266

**Principal Investigator: Stefan O. Ciurea, M.D.**

Schedule an appointment or make referral online at https:// my.mdanderson.org or call 713-563-2000. For more information about the study, contact Dr. Ciurea at 713-745-0146 or sciurea@mdanderson.org

For information on related articles or references for this study, visit http://physicianrelations.org or http://clinicltrials.gov/ct2/show/NCT01010217

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Making Cancer History®